BenzingaAugust 6, 2026 at 5:28 AM NY29 days ago

Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story